Codiak BioSciences, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development of exosome-based therapeutics. The Company has developed its engineering and manufacturing platform, engEx Platform, to develop upon the innate properties of exosomes to design, engineer and manufacture exosome therapeutics. It utilizes the engEx Platform to generate a pipeline of engineered exosomes (engEx) exosomes, focused at treating a range of diseases, including oncology, neuro-oncology, neurology, neuromuscular disease and infectious disease. The Company’s product candidates, exoSTING and exoIL-12, are developed to address solid tumors. The Company’s program, exoSTING, is an exosome therapeutic candidate engineered with its engEx Platform to carry stimulator of interferon genes (STING) agonist inside the lumen of the exosome while expressing prostaglandin F2 receptor negative regulator (PTGFRN).